Objectives: Tobacco exposure is an established risk factor for pancreatic cancer and chronic pancreatitis; however, its role in pancreatic insufficiency is not clear.
T obacco exposure is recognized as a cause of chronic disease in multiple organ systems through mechanisms that involve DNA damage, inflammation, and oxidative stress. 1, 2 In the pancreas, the impact of tobacco exposure has not been as well characterized as alcohol; however, there is increasing evidence that smoking is toxic to the pancreas and may have significant clinical implications. The pancreatic parenchyma manifests histologic changes in a dose-dependent manner with tobacco exposure, 3 and the amount of cigarette smoking per day correlates with advanced hyaline thickening in pancreatic arterioles. 3 There is a 75% increase in the risk of pancreatic cancer in smokers as compared with nonsmokers. 4, 5 Although not as widely recognized, smoking is emerging as an important risk factor in the etiology of chronic pancreatitis. 6 Multiple studies have demonstrated that smoking may potentiate the effects of alcohol, 7, 8 and may also be an independent risk factor for chronic pancreatitis 7, 9, 10 in a dose-dependent manner. 11 In patients with alcoholic chronic pancreatitis, exocrine pancreatic insufficiency was found only in patients with at least 15 packyears, and patients with 30 or more pack-years had exocrine pancreatic insufficiency at a significantly earlier age than those with less than 30 pack-years, suggesting a dose-response. 11 A large population screening study assessed patients for pancreatic insufficiency at enrollment and several risk factors emerged. Among these, patients with a self-reported history of smoking had a significantly increased odds of developing exocrine pancreatic insufficiency as compared with subjects who did not currently smoke. 12 These studies and clinical observations suggest that smoking is more toxic to the pancreas than is widely recognized and led to the hypothesis that pancreatic exocrine function may be significantly impacted by tobacco exposure before a diagnosis of pancreatic disease. This study enrolled patients with and without a history of heavy tobacco exposure to examine the relationship between smoking and pancreatic insufficiency in patients with no prior history of pancreatic disease. As frequent covariates, we further sought to distinguish the contributions of smoking and alcohol exposure on pancreatic exocrine function in this population.
MATERIALS AND METHODS

Design Overview
This study was reviewed and approved by the Institutional Review Board of the Emory University School of Medicine. All patients in the study provided written informed consent for participation. We performed a controlled cross-sectional analysis of patients recruited from primary care and subspecialty outpatient clinics between April and August of 2013 (clinicaltrials.gov NCT01988350). Participants completed validated questionnaires and interviews to obtain a focused medical, smoking, and alcohol consumption history. The focused medical history included patients' self-reported demographic information, medical diagnoses, medication list, and 5-year changes in weight. Heights, weights, and body mass index (BMI) from prior visits were also abstracted from the patients' electronic medical record when available. Smoking history was obtained via the validated National Health And Nutrition Examination Survey of Smoking and Cigarette Use, 13 and additionally a total lifetime smoking pack-year history was calculated. Alcohol consumption history was obtained via the validated Lifetime Drinking History Questionnaire. 14 
Setting and Participants
Patients were offered enrollment if they were at least 30 years of age, able to read, and could understand and sign the informed consent. Smokers and nonsmokers were recruited. Patients were excluded if they had a prior diagnosis of pancreatic insufficiency, a current or remote history of acute or chronic pancreatitis, any other pancreatic disease or malignancy, a history of pancreatic surgery, or a prior diagnosis of small bowel malabsorption or Celiac disease.
Exposure Definitions
Nonsmokers were defined as patients who had at least 7 years of abstinence from smoking and less than five cumulative packyear smoking history. Smokers were defined as patients who had a heavy smoking history of at least 20 pack-years. These definitions were based on the presence of changes in the pancreatic parenchyma, which became significant with a 20 pack-year smoking history. 11 The 30-year age limit for all patients enrolled was determined on the basis of the 20 pack-year requirement for the tobacco exposure cohort (the control cohort also needed to be old enough to potentially have had a 20 pack-year smoking history). Alcohol consumption was measured using the standard definition of 0.6 oz of pure alcohol per drink (12 oz of beer, 5 oz of wine, or 1.5 oz of hard liquor). Alcohol categories were defined as follows: abstainer, less than 0.25 drinks per week; light drinker, 0.25 to 3 drinks per week; moderate, 3 to 14 drinks per week; and heavy, more than 14 drinks per week. 15 
Outcomes and Follow-up
All participants provided a stool specimen that was assayed for the fecal elastase-1 (FE-1) level via a quantitative sandwich enzyme-linked immunosorbent assay 16 (ARUP Laboratories, Salt Lake City, Utah). Pancreatic insufficiency was defined as a FE-1 concentration of 200 μg/g or less. Mild to moderate pancreatic insufficiency was defined as a FE-1 level between 100 and 200 μg/g, and severe pancreatic insufficiency was defined as a FE-1 level of 99 μg/g or less.
17 FE-1 values greater than 200 μg/g were considered to indicate normal pancreatic function and no insufficiency. The results of the FE-1 testing were reported back to patients. All patients with abnormal FE-1 levels were offered follow-up with the pancreatology service outside of the study for clinical evaluation and management. FIGURE 1. Study enrollment. A total of 100 smokers and 100 non-smoker controls were ultimately enrolled in the study.
Statistical Analysis
Pancreatic glandular changes may be seen in approximately 5% of the general population and in 30% or more with a heavy smoking history (>20 cigarettes/day). 3 We hypothesized at least a 15% difference in the proportion of patients with low FE-1 levels in the tobacco exposure arm as compared with the nonsmoking control arm. Using a P value of 0.05 and a power of 80%, we estimated our sample size in each arm to be 88 subjects. Assuming a 10% dropout rate, the target enrollment cohort was 100 patients per arm. Univariate associations of smoking status and pancreatic insufficiency with covariates were examined with analysis of variance or Wilcoxon rank-sum tests for numerical covariates and χ 2 or Fisher exact test for categorical covariates. Independent t tests were used for continuous variables. A logistic regression model was further used to identify independent predictors of pancreatic insufficiency. A backward variable selection method with an α level of removal of 0.1 was used. Data were stored behind the institution's firewall and analyzed using the SAS 9.3 software (SAS Institute Inc, Cary, NC). Significance was defined as a P < 0.05.
RESULTS
Enrollment
Between April 2013 and August 2013, 7854 outpatients were approached. A total of 226 patients signed informed consent and agreed to further screening and interview. Twenty-four were subsequently excluded: 9 did not complete the questionnaire, 14 met exclusion criteria, and 1 patient was excluded due to tobacco use exclusively in the form of snuff. A total of 202 patients completed the screening process. Two of these provided inadequate stool specimens. The final cohort met the predetermined target enrollment and consisted of 100 smokers and 100 controls who were included in the final analysis (Fig. 1) .
Characteristics of Study Participants
Baseline demographic and clinical characteristics in each cohort are outlined in Table 1 . As compared with nonsmoking controls, smokers were slightly older (64.5 vs 60.5 years; P = 0.020), had a higher rate of diabetes (24% vs 13%; P = 0.045), and had dyslipidemia by history (58% vs 43%; P = 0.034). The tobacco exposure cohort also had a higher prevalence of marijuana use (6% vs 0%; P = 0.029) and greater alcohol consumption as described below.
Pancreatic Insufficiency
On univariate analysis, several characteristics were significantly associated with pancreatic insufficiency: tobacco exposure (P = 0.009), current smoker (P = 0.002), pack-years of smoking (P = 0.008), type of tobacco product used (P = 0.021), diabetes (P = 0.046), and marijuana use (P = 0.024) ( Table 2 ). Alcohol use, angiotensin-converting enzyme (ACE) inhibitor use, age, race, and measures of weight change were not significantly associated with pancreatic insufficiency. The prevalence of pancreatic insufficiency (FE-1, ≤200 μg/g) was 18% (18/100 patients) in the tobacco exposure cohort, significantly greater than in the nonsmoking control group with 6% (6/100 patients) (P = 0.009). In addition, 10% of the tobacco exposure cohort had severe pancreatic exocrine insufficiency (FE-1, <100 μg/g) as compared with 1% in the nonsmoker cohort (P = 0.010) (Fig. 2) .
Pancreatic Insufficiency and Weight Loss
The smokers with pancreatic insufficiency reported a mean weight loss of 12.7 kg during the 5 years before this study, or a loss of 2.54 kg/year, significantly greater than the self-reported weight loss in smokers without pancreatic insufficiency (3.1 kg weight loss, 0.62 kg/year loss; P < 0.001). Within the nonsmoker cohort, neither patients with pancreatic insufficiency nor patients To corroborate patient's self-reported weight change, the medical records were reviewed; however, historical weight data were not available for all patients. From the available data, smokers with pancreatic insufficiency averaged a weight loss of 0.51 kg/year, and smokers without pancreatic insufficiency averaged a weight loss of 0.43 kg/year. In the nonsmoking group, patients with pancreatic insufficiency averaged a weight loss of 0.41 kg/year, whereas patients without pancreatic insufficiency had an average weight gain of 0.38 kg/year.
Outcome Analysis
On multivariate logistic regression, the risk of pancreatic insufficiency in smokers, when controlled for covariates, was significantly increased [P = 0.012; odds ratio (OR), 4.34 (1.37-13.75)] (Table 3 ). In the multivariate model, tobacco exposure was associated with the highest OR for pancreatic insufficiency, with smokers having greater than fourfold increased risk. Hyperlipidemia was significantly and inversely associated with the presence of pancreatic insufficiency [P = 0.009; OR, 0.20 (0.06-0.67)]. The association of diabetes mellitus and pancreatic insufficiency was borderline in the multivariate model [P = 0.056; OR, 3.27 (0.97-11.02)]. Age, sex, BMI, ACE inhibitor use, and alcohol use were also included in the final multivariable model; however, none were independently or significantly associated with pancreatic insufficiency.
Effects of Alcohol Consumption
Smokers had a higher prevalence of alcohol consumption at any level than nonsmokers (86% vs 61%; P < 0.001) ( Table 1) . Alcohol use was associated with smoking; however, on both univariate analysis and multivariate logistic regression, alcohol consumption at any level was not significantly associated with pancreatic insufficiency (P = 0.671 and P = 0.792, respectively) (Tables 2 and 3 ).
DISCUSSION
The impact of tobacco exposure on the pancreas is being increasingly recognized. Tobacco exposure seems to damage the pancreatic parenchyma, 3 to increase the risk of pancreatic cancer, [3] [4] [5] and has a clear although underappreciated impact on the development of chronic pancreatitis. 7, 11, 18 This study identified pancreatic insufficiency in a high proportion of smokers with no prior history of pancreatic disease. The prevalence rate in smokers (18%) significantly exceeded the rate found in the nonsmoking control population (6%) (P = 0.009). The rate of severe pancreatic insufficiency was also significantly increased in the tobacco exposure cohort (P = 0.010). The relationship seemed to be independent of alcohol consumption, and tobacco exposure was the strongest predictor of pancreatic insufficiency in the multivariate model [OR, 4.34; confidence interval (CI), 1.37-13.75; P = 0.012]. Tobacco exposure seems to be detrimental to pancreatic exocrine function before the development of chronic pancreatitis and seems to be an independent risk factor for the The reference category for all levels of alcohol use was abstainers. ‡ Perceived 5-year weight change is the patient's self-reported change in weight over the 5 years before the study, reported in kilograms. § Actual weight change is the patient's recorded weight in kilograms at the time of the interview minus the recorded weight in kilograms either five years earlier, or the earliest recorded weight within the five years before the study. development of pancreatic insufficiency in the absence of previously established or known morphologic disease of the pancreas.
Numerous nutritional deficiencies occur in smokers. Recent trials evaluating nutritional markers in smokers and nonsmokers have revealed decreases in plasma levels of vitamin C, vitamin B12, red cell folate, and albumin in smokers, [19] [20] [21] and tobacco exposure has been associated with significant reductions in body weight, BMI, and other anthropometric markers of nutritional status. 19 In our study, smokers self-reported weight loss, and this relationship was corroborated in the subset with prior weight data. Although the etiology for compromised nutritional status is not well understood, several mechanisms have been proposed. One hypothesis suggests an impaired oxidation state as a result of free radical production by cigarette smoking, leading to a depletion of the intracellular antioxidants vitamin E, vitamin C, and β-carotene. 22 Other postulated mechanisms include poor dietary intake of protein, fruits, vegetables, fiber, and essential nutrients. 23 An increased work of breathing combined with difficulty eating while experiencing dyspnea has also been hypothesized. 24 In our study, hyperlipidemia by history was more common in the smoker cohort; however, it was inversely related to pancreatic insufficiency in the multivariate analysis. We believe that the relationship is complex-smokers may have more dyslipidemia overall due to lifestyle factors; however, dyslipidemia may be decreased in patients with pancreatic insufficiency due to fat malabsorption. Overall, pancreatic insufficiency may be involved in the nutritional deficiencies seen in smokers and may well be a contributor to the weight loss seen in patients with heavy tobacco exposure.
Alcohol has been considered to be the primary toxic exposure leading to disease of the pancreas and is the clear established risk factor for the development of chronic and calcific pancreatitis. In this study, alcohol was associated with smoking, with more smokers reporting higher prior levels of alcohol consumption. However, tobacco seemed to be the primary toxic exposure in terms of pancreatic insufficiency in the cohort of patients without established pancreatic disease. Tobacco exposure may also have been an underrecognized comorbid exposure in previous studies examining the impact of alcohol on disease of the pancreas. Several prior studies analyzing the relationship between alcohol and the etiology, course, and sequelae of chronic pancreatitis did not report on tobacco exposure in the study population. [25] [26] [27] When included, greater cigarette smoke and nicotine exposure have had a direct relationship with chronic pancreatitis in humans. 28 Although this study focused on the exocrine manifestations of pancreatic disease, there was also an association with endocrine dysfunction. We found a relationship between diabetes and both smoking and pancreatic insufficiency. On univariate analysis, smokers had a significantly higher prevalence of diabetes as compared with the control cohort. Diabetes was borderline in the multivariate model (P = 0.056). These findings are in line with previous reports that have found a pooled relative risk of diabetes in smokers of 1.44 with a dose-response relationship. 29 There are several potential limitations in this trial. The study population was obtained from a single center. Many patients were not willing or able to provide a stool sample, leading to the need to approach a large number of patients to enroll the target cohort. This could have introduced an element of volunteer bias, which if present would hopefully have been similar in each arm of the study. The historic data in the area of weight were not available for all patients, as some patients who enrolled were new to the clinics. In addition, FE-1 is not a perfect marker of pancreatic insufficiency, with variability and the potential for false positives and negatives. However, FE-1 is the best noninvasive marker of pancreatic insufficiency with a sensitivity and specificity of 93% 16, 17 ; presumably, variations in test results would be equally distributed between the groups. Direct pancreatic function testing with timed duodenoscopic measurement of secretin or CCK has been previously identified as the gold standard; however, it would be difficult to justify invasive testing for pancreatic function in patients without known pancreatic disease.
This study suggests that tobacco exposure may be independently associated with decreased pancreatic exocrine function. Tobacco exposure had the strongest association with pancreatic insufficiency in multivariate modeling, persisting with control for covariates, most importantly alcohol exposure. Eighteen percent of patients with heavy tobacco exposure had a low fecal elastase without a history of chronic pancreatitis or known pancreatic disease. These results agree with prior studies that implicate tobacco exposure in histologic changes, chronic pancreatitis, and pancreatic cancer. The results also raise questions regarding the mechanism of weight loss in heavy smokers. Tobacco exposure seems to be associated with the development of pancreatic insufficiency, and the relationship may manifest before patients have come to clinical recognition or have developed symptoms of pancreatic disease.
